Literature DB >> 32040706

Gene expression profile of immunoregulatory cytokines secreted from bone marrow and adipose derived human mesenchymal stem cells in early and late passages.

Maryam Moghadam1, Samaneh Tokhanbigli1, Kaveh Baghaei2, Shirin Farivar3, Hamid Asadzadeh Aghdaei1, Mohammad Reza Zali4.   

Abstract

Mesenchymal Stem Cells (MSCs) have therapeutic potential in a variety of diseases; however, the safety and efficacy of their use remain ambiguous. Clinical applications of MSCs are under intensive investigation due to their immunomodulatory features and lack of immune reactivity. Therefore, having a clear perspective on the exact mechanisms underlying the regulation of cytokine secretion in different microenvironments seems crucially important.In the current study, samples from human bone marrow and adipose were collected, and peripheral blood mononuclear cells (PBMCs) were isolated and cultured in conventional medium. After MSC expansion, the cells from passage 3 (P3) and passage 9 (P9) were utilized to identify MSC cell surface markers and their differentiation capacity. The P3, P5, P7, and P9 cells were used for RNA extraction to qualify the expression of the main immunomodulatory cytokines IDO, VCAM-1, TGF-β, IL-6, IL-10, and PGE2 at mRNA levels. The results indicate that VCAM-1 expression in the subcultures was reduced in bone marrow-derived MSCs. After an increase in P5, P7, and P9, IL-6 expression was reduced. In adipose-derived MSCs, the mRNA levels of IL-10 in higher passages were decreased compared with P3; other studied cytokines had no significant changes in their expression levels in either bone marrow or adipose-derived MSCs. Based on these results, it can be concluded that a suitable source for MSCs in cell therapy with stable expression of main cytokines, even in higher subcultures, appears to be adipose-derived MSCs with the exception of IL-10 secretion.

Entities:  

Keywords:  Adipose-derived MSCs; Bone marrow-derived MSCs; Inflammatory and anti-inflammatory cytokines; Passage number

Mesh:

Substances:

Year:  2020        PMID: 32040706     DOI: 10.1007/s11033-020-05264-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  12 in total

1.  MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease.

Authors:  L Kordelas; V Rebmann; A-K Ludwig; S Radtke; J Ruesing; T R Doeppner; M Epple; P A Horn; D W Beelen; B Giebel
Journal:  Leukemia       Date:  2014-04       Impact factor: 11.528

Review 2.  Pluripotent stem cells progressing to the clinic.

Authors:  Alan Trounson; Natalie D DeWitt
Journal:  Nat Rev Mol Cell Biol       Date:  2016-03       Impact factor: 94.444

3.  Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.

Authors:  Guangwen Ren; Xin Zhao; Liying Zhang; Jimin Zhang; Andrew L'Huillier; Weifang Ling; Arthur I Roberts; Anh D Le; Songtao Shi; Changshun Shao; Yufang Shi
Journal:  J Immunol       Date:  2010-02-03       Impact factor: 5.422

Review 4.  Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases.

Authors:  Yufang Shi; Yu Wang; Qing Li; Keli Liu; Jianquan Hou; Changshun Shao; Ying Wang
Journal:  Nat Rev Nephrol       Date:  2018-08       Impact factor: 28.314

5.  Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).

Authors:  Anders Bruun Mathiasen; Abbas Ali Qayyum; Erik Jørgensen; Steffen Helqvist; Anne Fischer-Nielsen; Klaus F Kofoed; Mandana Haack-Sørensen; Annette Ekblond; Jens Kastrup
Journal:  Eur Heart J       Date:  2015-04-29       Impact factor: 29.983

6.  Intrinsic Variability Present in Wharton's Jelly Mesenchymal Stem Cells and T Cell Responses May Impact Cell Therapy.

Authors:  Fernanda Vieira Paladino; Luiz Roberto Sardinha; Carla Azevedo Piccinato; Anna Carla Goldberg
Journal:  Stem Cells Int       Date:  2017-07-05       Impact factor: 5.443

7.  Angiotensin II Attenuates the Bioactivities of Human Endothelial Progenitor Cells via Downregulation of β2-Adrenergic Receptor.

Authors:  Seon Jin Lee; Da Yeon Kim; Jisoo Yun; Sung Hyun Choi; Seok Yun Jung; Songhwa Kang; Ji Hye Park; Yeon Ju Kim; Jong Seong Ha; Seung Taek Ji; Woong Bi Jang; Dong Hyung Lee; Dongjun Lee; Sang-Mo Kwon
Journal:  Stem Cells Int       Date:  2018-10-29       Impact factor: 5.443

8.  Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion.

Authors:  Ekaterina Ivanova-Todorova; Ivan Bochev; Rumen Dimitrov; Kalina Belemezova; Milena Mourdjeva; Stanimir Kyurkchiev; Plamen Kinov; Iskra Altankova; Dobroslav Kyurkchiev
Journal:  J Biomed Biotechnol       Date:  2012-11-20

Review 9.  Mesenchymal stem cells and immunomodulation: current status and future prospects.

Authors:  F Gao; S M Chiu; D A L Motan; Z Zhang; L Chen; H-L Ji; H-F Tse; Q-L Fu; Q Lian
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

10.  Isolation, differentiation, and characterization of mesenchymal stem cells from human bone marrow.

Authors:  Kaveh Baghaei; Seyed Mohmoud Hashemi; Samaneh Tokhanbigli; Ali Asadi Rad; Hamid Assadzadeh-Aghdaei; Abdolhamid Sharifian; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017
View more
  1 in total

Review 1.  Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease.

Authors:  Mengqin Yuan; Xue Hu; Lichao Yao; Yingan Jiang; Lanjuan Li
Journal:  Stem Cell Res Ther       Date:  2022-05-03       Impact factor: 8.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.